Search Results for 'Relapsed'

Relapsed published presentations and documents on DocSlides.

$The Biology of Relapsed and Refractory Multiple Myeloma$

The Biology of Relapsed and Refractory Multiple Myeloma

by alexa-scheidler

Topics. Current Treatment Options for Relapsed/Re...

$Relapsed and Refractory Myeloma$

Relapsed and Refractory Myeloma

by jane-oiler

Ruben Niesvizky. Myeloma Center. Myelomacenter.or...

How I treat relapsed childhood acute

How I treat relapsed childhood acute

by trish-goza

lymphoblastic leukemia. . Franco Locatelli, Ma...

$Relapsed or Relapsed/Refractory$

Relapsed or Relapsed/Refractory

by alexa-scheidler

5 Multiple Myeloma SANDRA E. KURTIN, RN, MS, AOCN

$Improving Therapy Outcomes in Relapsed/Refractory$

Improving Therapy Outcomes in Relapsed/Refractory

by celsa-spraggs

Hodgkin Lymphoma. Program Objectives. Brentuximab...

by tatiana-dople

Agents . for . Indolent . L. ymphoma . and . Mant...

Recurrent Follicular Lymphoma

Recurrent Follicular Lymphoma

by sherrill-nordquist

With a Short First Remission:. How Aggressive Sho...

Ibrutinib : First-in Class Inhibitor of BTK

Ibrutinib : First-in Class Inhibitor of BTK

by briana-ranney

Forms a specific and irreversible bond with cyste...

Activity Faculty Scott C. Howard, MD,

Activity Faculty Scott C. Howard, MD,

by tatiana-dople

MSc. University of Tennessee College of . Health ...

Recurrent HL after Auto

Recurrent HL after Auto

by karlyn-bohler

T. ransplant . in CR on . B. rentuximab. . V. ed...

$Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive NHL?$

Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive NHL?

by mitsue-stanley

Bertrand Coiffier. Service d. ’. Hématologie. ...

Chronic lymphocytic leukemia,

Chronic lymphocytic leukemia,

by natalia-silvester

New agents timing?. Agne Paner, MD. Assistant pro...

by jane-oiler

R. esidual . D. isease in AML. Steven M. Kornblau...

MEK Inhibitors and their potential role in relapsed NSCLC

MEK Inhibitors and their potential role in relapsed NSCLC

by debby-jeon

Ranee Mehra, MD. Fox Chase Cancer Center. Philade...

Brentuximab Vedotin.

Brentuximab Vedotin.

by luanne-stotts

How and When Should it be Used in B and T cell Ly...

by marina-yarberry

therapy in relapsed/refractory myeloma: . A UK m...

Selecting Therapy for Relapsed/

Selecting Therapy for Relapsed/

by tawny-fly

Refractory Multiple Myeloma. Case #1. Monitoring ...

$Personalized Therapy in Relapsed or Refractory CLL$

Personalized Therapy in Relapsed or Refractory CLL

by kittie-lecroy

IWCLL Criteria for Treating CLL. Other Considerat...

Ibrutinib for Hairy Cell Leukemia

Ibrutinib for Hairy Cell Leukemia

by pasty-toler

. A Brief Update of an Ongoing Trial. Jeff Jones...

Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

by conchita-marotz

ASH Review 2012. Stephen Spurgeon (spurgeos@ohsu....

$Relapsed/Refractory Follicular Lymphoma Conundrums$

Relapsed/Refractory Follicular Lymphoma Conundrums

by danika-pritchard

This program will include a discussion of off-lab...

Case Discussion A 64-year old woman diagnosed with monoclonal

Case Discussion A 64-year old woman diagnosed with monoclonal

by faustina-dinatale

Case Discussion A 64-year old woman diagnosed wit...

Please note, these are the actual video-recorded

Please note, these are the actual video-recorded

by rayfantasy

proceedings from the live CME event and may includ...

Please note, these are the

Please note, these are the

by ryotheasy

actual. . video-recorded proceedings from the . l...

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and

by scoopulachanel

Myeloma. 1. Safety and Efficacy of Daratumumab wit...

$Pivotal Safety and Efficacy Results From TRANSCEND NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphomas$

Pivotal Safety and Efficacy Results From TRANSCEND NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphomas

by botgreat

Lisocabtagene. . Maraleucel. in Relapsed/Refract...

CAR-T Therapy in non-Hodgkin lymphomas

CAR-T Therapy in non-Hodgkin lymphomas

by natalie

Jonathon B. Cohen, MD. Dept of . Hematology. /Medi...

Ro le of Stem Cell Transplant in Patients with Peripheral T-Cell

Ro le of Stem Cell Transplant in Patients with Peripheral T-Cell

by sylvia

Lymphoma and Response to Treatment Strategies . IN...

x0000x0000 xAttxachexd xBottxom xBBoxx

x0000x0000 xAttxachexd xBottxom xBBoxx

by evans

Chimeric Antigen Receptor Tcell TherapyClinical Gu...

Relapse in Chronic Myeloid

Relapse in Chronic Myeloid

by ella

A Guide for A relapse is the return of leukaemia ...

stanbul Med J 2019 201 358

stanbul Med J 2019 201 358

by emily

35 ÖZ Pes ekinovarus (PEV) sekellerine ve nüksl...

Understanding Lymphoma Series

Understanding Lymphoma Series

by evans

Helpline: 800 500 9976 | helpline@lymphoma.org U...

Supervisor: VS 高志平

Supervisor: VS 高志平

by jovita

Reporter: R4 . 張妙而. Introduction. . Mutatio...

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

by willow

Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...

Aktuelle Therapieempfehlungen beim Multiplen

Aktuelle Therapieempfehlungen beim Multiplen

by brown

Myelom. Heinz . Gisslinger. Medizinische Universit...

$AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgki$

AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgki

by cesar673

+. Peripheral T-Cell Lymphoma: A Phase 2 Study (L...

SWAG Protocols update March 2024

SWAG Protocols update March 2024

by nehemiah176

Kate Gregory. Lead Pharmacist for SWAG Protocols �...